Cataract senilis
Conditions
Interventions
Trade Name: Nevanac 1mg/ml
Product Name: Nevanac 1mg/ml
Product Code: S01GX09
Pharmaceutical Form: Ear drops, suspension
Trade Name: Pred Forte 10mg/ml
Product Name: Pred Forte 10mg/ml
Pharmaceutical
Sponsors
Raimo Tuuminen
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Pseudoexfoliation Age 60-90 years Fullfills national criteria for cataract surgery Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 30 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 120
Exclusion criteria
Exclusion criteria: Diabetes. Active wet AMD /planned anti-VEGF therapy prior retinal vein/artery occlusion, retinal detachment, optic neuritis, vitreous hemorrhage, intraocular surgery. Myopia magna. Pregnancy. Alcohol misuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To study efficacy of corticosteroid and nonsteroidal anti-inflammatory drug therapy in management of post-operative inflammation and prevention of pseudophakic cystic macular edema after uncomplicated cataract surgery in pseudoexfoliation eyes;Secondary Objective: To study corticosteroid and nonsteroidal antiinflammatory drug therapy on perioperative discomfort and recovery from uncomplicated cataract surgery in pseudoexfoliation eyes;Primary end point(s): Best corrected visual acuity, central retinal thickness, aqueous flare;Timepoint(s) of evaluation of this end point: 1 and 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Intraocular pressure, postoperative discomfort and recovery from surgery;Timepoint(s) of evaluation of this end point: The first postoperative days and 3 months | — |
Countries
Finland
Contacts
Public ContactClinical Trials Information
Raimo Tuuminen
Outcome results
None listed